| PANOP INJECTION | Pantaprazole injections |
|---|---|
|
|
| Composition : | Each vial contains 40 mg of pantoprazole (as sodium sesquihydrate) |
| Indications : | Reflux oesophagitis Gastric and duodenal ulcer Zollinger – Ellison Syndrome and other pathological hypersecretory conditions. |
| Contraindications : | Hypersensitivity to the active substance, substituted benzimidazoles, or to any of the excipients. |
| Adverse Effects : | Diarrhea and headache, Injection site thrombophlebitis, Asthenia, fatigue and malaise, nausea/ vomiting; abdominal distension and bloating; constipation; dry mouth; abdominal pain and discomfort |
| Dosage : | Gastric and duodenal ulcer, reflux oesophagitis The recommended intravenous dose is one vial of pantoprazole (40 mg) per day. Zollinger-Ellison Syndrome and other pathological hypersecretory conditions For the long-term management of Zollinger-Ellison Syndrome and other pathological hypersecretory conditions patients should start their treatment with a daily dose of 80 mg of pantoprazole i.v. Thereafter, the dosage can be titrated up or down as needed using measurements of gastric acid secretion to guide. With doses above 80 mg daily, the dose should be divided and given twice daily. A temporary increase of the dosage above 160 mg pantoprazole is possible but should not be applied longer than required for adequate acid control. In case a rapid acid control is required, a starting dose of 2 x 80 mg of pantoprazole i.v. is sufficient to manage a decrease of acid output into the target range (<10 mEq/h) within one hour in the majority of patients. |
PANOP INJECTION
- DateNovember 10, 2017